Blueprint Medicines Corp (BPMC)
106.25
-0.94
(-0.88%)
USD |
NASDAQ |
May 06, 16:00
106.24
-0.01
(-0.01%)
After-Hours: 20:00
Blueprint Medicines Gross Profit (TTM): 273.65M for March 31, 2024
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 273.65M |
December 31, 2023 | 240.84M |
September 30, 2023 | 203.08M |
June 30, 2023 | 212.27M |
March 31, 2023 | 188.68M |
December 31, 2022 | 186.22M |
September 30, 2022 | 251.76M |
June 30, 2022 | 209.18M |
March 31, 2022 | 198.32M |
Date | Value |
---|---|
December 31, 2021 | 162.15M |
September 30, 2021 | 96.65M |
June 30, 2021 | 821.23M |
March 31, 2021 | 808.64M |
December 31, 2020 | 793.31M |
September 30, 2020 | 810.86M |
June 30, 2020 | 75.03M |
March 31, 2020 | 71.92M |
December 31, 2019 | 66.51M |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (TTM) Range, Past 5 Years
66.51M
Minimum
Dec 2019
821.23M
Maximum
Jun 2021
315.02M
Average
206.13M
Median
Gross Profit (TTM) Benchmarks
Apellis Pharmaceuticals Inc | 338.08M |
Alnylam Pharmaceuticals Inc | 1.682B |
Ionis Pharmaceuticals Inc | 778.51M |
Madrigal Pharmaceuticals Inc | -- |
Sarepta Therapeutics Inc | 1.237B |